Endometrial cancer stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:19:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Endometrial cancer stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of dostarlimab treatment before surgery in patients with stage II-III endometrial cancer with specific genetic markers https://clinicaltrials.eu/trial/study-of-dostarlimab-treatment-before-surgery-in-patients-with-stage-ii-iii-endometrial-cancer-with-specific-genetic-markers/ Wed, 29 Apr 2026 15:07:22 +0000 https://clinicaltrials.eu/trial/study-of-dostarlimab-treatment-before-surgery-in-patients-with-stage-ii-iii-endometrial-cancer-with-specific-genetic-markers/ This study focuses on patients with endometrial cancer, specifically stage II-III disease with certain genetic characteristics (MMRd/MSI-H). Endometrial cancer is a type of cancer that begins in the lining of the uterus. The study will test a medication called dostarlimab, which is given through an intravenous infusion (delivered directly into a vein).

The purpose of this research is to evaluate how well dostarlimab works when given before surgery (as neoadjuvant therapy) in treating this specific type of endometrial cancer. During the study, participants will receive dostarlimab infusions, with each dose being 500 mg. The treatment may continue for up to 66 weeks, with regular medical check-ups to monitor the patient’s condition.

Throughout the study, doctors will use various imaging tests such as MRI, CT scan, and PET scan to check how the cancer responds to treatment. They will also perform physical examinations and monitor for any side effects. The total amount of dostarlimab that a patient might receive during the entire study period could reach up to 12,000 mg.

]]> Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer https://clinicaltrials.eu/trial/study-on-dostarlimab-carboplatin-and-paclitaxel-for-patients-with-recurrent-or-advanced-endometrial-cancer/ Wed, 29 Apr 2026 14:27:22 +0000 https://clinicaltrials.eu/trial/study-on-dostarlimab-carboplatin-and-paclitaxel-for-patients-with-recurrent-or-advanced-endometrial-cancer/ This clinical trial is focused on studying treatments for endometrial cancer, which is a type of cancer that begins in the lining of the uterus. The study involves patients with recurrent or primary advanced stages of this cancer. The main treatment being tested is a medication called Dostarlimab, also known by its code name TSR-042. Dostarlimab is a type of drug known as a monoclonal antibody, which is designed to help the immune system fight cancer cells. In this study, Dostarlimab is combined with two chemotherapy drugs, Carboplatin and Paclitaxel, and compared to a combination of a placebo with Carboplatin and Paclitaxel. Additionally, another medication called Niraparib is being tested in combination with Dostarlimab in some parts of the study.

The purpose of the study is to determine if adding Dostarlimab to the standard chemotherapy treatment can delay the return of cancer or improve survival rates in patients with advanced endometrial cancer. The study is divided into two parts. In the first part, patients receive either Dostarlimab with chemotherapy or a placebo with chemotherapy. In the second part, some patients receive Dostarlimab with Niraparib and chemotherapy, while others receive a placebo with chemotherapy. The study is designed to be double-blind, meaning neither the patients nor the researchers know who is receiving the actual medication or the placebo, to ensure unbiased results.

Participants in the study will receive treatment over a period of time and will be monitored regularly to assess the progression of their cancer and overall health. The study aims to provide valuable information on the effectiveness of Dostarlimab and Niraparib in treating advanced endometrial cancer, potentially leading to improved treatment options for patients in the future.

]]>